Executive summary
US Patent 9,089,418 covers an intrauterine contraceptive device for localized uterine delivery that combines (i) a shape-memory elongate member with a loop, spring-like multiple twists, and a cross-over/two-bend geometry that forms two arms with tissue-contact ends, and (ii) multiple delivery sleeves coupled along each arm and below the twists to deliver a contraceptive substance in two uterine target regions near a fallopian tube and near a cervical os. Claim scope is anchored on the structural combination: shape-memory member architecture plus at least three sleeves positioned on the two arms and below the twists. Dependent claims add stiffness-by-twist count, substance-type limitations (copper/spermicidal), copper dose/“sleeve” surface-area cap (≤200 mm² total), and optional concurrent hormone delivery. The patent estate is likely to function as a core claim on device geometry and sleeve placement rather than dose mechanics alone; design-arounds can be targeted at sleeve count/placement, elimination or alteration of the cross-over two-bend geometry, and substitution of non-shape-memory biasing elements.
What is US Patent 9,089,418 and what does it claim about uterine localized drug delivery?
US 9,089,418 is directed to a contraceptive device for localized delivery of a substance within the uterus. The independent claim (claim 1) is a structural composite claim: it requires both (a) a specific shape-memory member geometry used as a spring/biasing element and (b) multiple substance delivery sleeves coupled at specific locations on the member for localized delivery near two anatomical targets.
Core limitations in claim 1 (independent claim)
Claim 1 requires, in combination:
- “Contraceptive device for localized delivery … in a uterus”
- An elongate shape memory member with the following sub-structures:
- A loop portion at the bottom of the device
- A middle portion extending upward from the loop
- Multiple twists in the middle portion acting as a spring portion
- Two bends at a location above the multiple twists where the elongate member crosses over itself
- Two arms extending from the bends, where each arm extends from a respective bend
- Two tissue contact surfaces at the ends of the two arms
- Multiple substance delivery sleeves coupled to the elongate member at locations configured to locally deliver substance to:
- an area near a fallopian tube and
- an area near a cervical os
- Sleeve structure:
- First sleeve disposed at least partially around the elongate member on the first arm near the first tissue contact surface
- Second sleeve disposed at least partially around the elongate member on the second arm near the second tissue contact surface
- Third sleeve disposed at least partially around the elongate member below the twists
Claim architecture implication
Because claim 1 is written as a “device comprising” list, the accused device must include all recited components and their coupling/placement relationships. Missing any one of: (i) shape-memory member, (ii) twist spring portion, (iii) the two-bend cross-over geometry, (iv) two-arm arrangement with tissue-contact ends, or (v) at least three sleeves with their specific positional relationships, is the clearest pathway to non-infringement.
How broad are the independent claim 1 scope and boundaries for the shape-memory and sleeve architecture?
Claim 1’s breadth comes from two aspects: it is technology-defined (shape-memory + sleeve delivery) but not limited to a specific sleeve material, coating process, sleeve permeability, or exact uterine spacing distances. At the same time, it is narrow where it requires specific geometric relationships (cross-over bends above twists; sleeves on both arms near tissue contact surfaces; third sleeve below twists).
What makes claim 1 relatively broad
- Substance is not limited in claim 1 beyond being “a substance” configured for localized delivery. Specific substance types are handled in dependent claims (copper/spermicidal; hormone).
- The claim does not specify:
- exact uterine placement depth,
- exact sleeve dimensions other than dependent claim 4,
- specific membrane/sleeve permeability,
- elution kinetics,
- sleeve number beyond the “multiple sleeves” defined as first, second, and third in claim 1.
What makes claim 1 relatively narrow
- Shape-memory member architecture is tightly specified:
- loop at bottom,
- multiple twists acting as spring portion,
- two bends above the twists with a cross-over,
- two arms extending from the bends,
- two tissue contact surfaces at ends of those arms.
- Sleeve placement is tied to both anatomy and device geometry:
- first sleeve on arm 1 near tissue-contact surface 1,
- second sleeve on arm 2 near tissue-contact surface 2,
- third sleeve below twists.
- Claim 1 requires the sleeves to be “coupled” with the elongate shape memory member, and disposed “at locations” for target regions near the fallopian tube and cervical os. That couples geometry to therapeutic positioning.
Literal infringement hotspots
- A device using a single sleeve around one arm, or two sleeves without a third below the twists, risks missing claim 1’s explicit sleeve set-up.
- A device that has arms but no “two bends” cross-over above twists likely misses the recited geometry.
- A device that replaces the “elongate shape memory member” with a non-shape-memory spring wire or polymer biasing element likely misses that limitation.
Which design elements must be present to infringe claim 1?
Below are the minimum “must-have” elements under claim 1.
Device architecture must-haves
- An elongate shape memory member
- A loop at the bottom
- A middle portion with multiple twists acting as a spring portion
- Two bends above the twists where the member crosses over itself
- Two arms extending from the bends
- Two tissue contact surfaces at two ends of the arms
- At least three delivery sleeves:
- sleeve 1: around arm 1 near tissue contact surface 1
- sleeve 2: around arm 2 near tissue contact surface 2
- sleeve 3: around member below twists
Therapeutic/functional placement must-haves
- Sleeves configured to deliver substance:
- in an area near a fallopian tube, and
- in an area near a cervical os.
Even if “near” is litigated as a distance/placement concept, the claim requires that the sleeves are located for those target areas. A device with sleeves that elute into different uterine regions (for example, only fundal region) risks non-infringement.
What do dependent claims 2–6 add and how do they change infringement risk?
Claim 2: stiffness defined by twist count
“Wherein a number of the multiple twists of the spring portion at least in part defines a stiffness of the device.”
Effect on scope:
- Narrows to devices where the number of twists is used (at least in part) to define the stiffness.
- A design with twist count fixed but stiffness defined mainly by material thickness, heat treatment, outer sleeve geometry, or polymer coating may argue non-infringement of claim 2 (though claim 1 could still be met if claim 1 elements are present).
Claim 3: substance selected from copper and other spermicidal agents
Narrows to contraceptive substances limited to:
- copper, and
- other spermicidal agents.
Effect:
- If the substance is a hormone only, or a different drug not in that group, claim 3 is not met. Claim 1 could still be met depending on whether claim 1’s “substance” limitation is broader and whether the substance falls within claim 1’s general term.
Claim 4: copper + total sleeve surface area cap
“Narrowing” limitations:
- Substance comprises copper
- Substance delivery sleeves have total surface area ≤ about 200 square millimeters
Effect:
- Creates a quantitative design boundary. A copper device with sleeves exceeding that surface area could avoid claim 4 while still potentially infringing claims 1 and 3 (and possibly claim 1).
- The term “total surface area” and whether it includes both outer and inner surfaces, ends, and overlaps is a likely claim-construction point, but the key practical infringement design variable is the numeric cap.
Claim 5: copper + optional hormone delivery member
“Substance comprises copper” and “device further comprises a hormone delivery member coupled with the elongate member.”
Effect:
- Narrows to dual-delivery configurations: copper plus hormone on the device.
- If a competitor uses hormone plus copper but not a “hormone delivery member coupled with the elongate member,” it may avoid claim 5 while still falling within claim 1 depending on interpretation.
Claim 6: substance comprises a hormone
Narrows substance to hormone.
Effect:
- If the device contains a hormone, claim 6 is relevant. For devices that contain copper plus hormone, claim 6 might be satisfied depending on whether “substance comprises a hormone” is construed to allow copper as well (the phrase “comprises” typically is permissive).
How strong is the patent estate for blocking competing IUD-like localized delivery devices?
Strength is determined by what the independent claim captures and how many plausible designs can avoid each critical element.
Most defensible claim features
- Shape-memory member + spring twists: many competitor IUD insertion and retention structures use mechanical springs or polymer deformation, not shape-memory twist/spring geometries.
- Cross-over two-bend geometry above twists: this is a relatively specific mechanical arrangement that is less likely to be replicated unintentionally.
- Three-sleeve coupling with sleeve-specific placement: requiring sleeve 1 on arm near tissue-contact end, sleeve 2 on the opposite arm near tissue contact end, and sleeve 3 below twists ties mechanical structure to drug distribution.
Where competitors can carve out
- Replace shape-memory material with a different biasing structure.
- Modify sleeve count (for example, two sleeves only) or relocate sleeves away from “below the twists” or away from “near tissue contact surfaces.”
- Remove the specific two-bend cross-over arrangement, for example by using separate arms that do not require cross-over above the twists.
- For copper-specific variants, exceed or avoid the ≤200 mm² total sleeve surface-area limitation to avoid claim 4.
What patent landscaping indicators matter for US 9,089,418 in litigation and licensing?
A full landscape requires bibliographic extraction from USPTO/Orange Book and citation history, which is not provided here. Still, the claim text itself reveals a typical enforcement pattern for device patents: focus on literal infringement of geometric relationships and sleeve placement, then argue equivalents for near-substitutions (for example, “below the twists” location variants).
Claim-to-landscape enforcement likely strategy
- Primary asserted target: claim 1. Dependent claims create fallback positions for specific commercial embodiments (copper-only, copper+surface cap, copper+hormone).
- Non-infringement defenses to prepare:
- no shape-memory member,
- spring portion not “multiple twists” as claimed,
- no two bends with cross-over above twists,
- sleeves not positioned as “first/second near tissue-contact ends” and “third below twists,”
- copper sleeve total surface area >200 mm² if copper-only product is accused under claim 4.
What would be the likely commercial exposure for companies selling uterine localized copper/hormone delivery devices?
Exposure concentrates on products that market as:
- uterine localized drug delivery with multiple local release regions, and
- device architecture resembling a frame with spring-like bias plus local drug reservoirs at both sides and a third lower region.
Because claim 1 requires both fallopian tube-near and cervical os-near delivery regions, products delivering only fundal/central uterine drug without side-specific near-tube delivery are less exposed.
How does US 9,089,418 compare with typical IUD patents focused on copper wire, reservoir shape, or hormone core?
Typical IUD/hormone reservoir patents often focus on:
- copper wire geometry and contact with uterine lining,
- polymer coatings and diffusion paths,
- hormone dose form and release kinetics,
- insertion sleeves and retention tails.
US 9,089,418 is device-mechanical + delivery-structure hybrid:
- It ties delivery sleeves to a specific shape-memory spring and cross-over arm geometry.
- It adds a quantitative copper sleeve surface area cap in claim 4.
- It explicitly includes the “third sleeve below the twists,” which many reservoir designs do not treat as a distinct structural element.
That combination increases the odds that competitors must substantially alter device geometry to avoid infringement.
Claim chart style breakdown (for infringement mapping)
This is a direct element-by-element checklist based on claim text.
Claim 1 mapping checklist
- Contraceptive device for localized delivery in uterus
- Elongate shape memory member
- Loop portion at bottom
- Middle portion extending upward from loop
- Multiple twists in middle portion acting as spring portion
- Two bends above twists where elongate member crosses over itself
- Two arms extending from bends
- Tissue contact surfaces at ends of arms (two ends)
- Multiple substance delivery sleeves coupled to elongate member for delivery near:
- fallopian tube area
- cervical os area
- First sleeve around member on first arm near first tissue contact surface
- Second sleeve around member on second arm near second tissue contact surface
- Third sleeve around member below twists
Dependent claims mapping
- Claim 2: twist count defines stiffness
- Claim 3: substance is copper or other spermicidal agents
- Claim 4: copper + total sleeve surface area ≤200 mm²
- Claim 5: copper + hormone delivery member coupled to elongate member
- Claim 6: substance comprises hormone
Key Takeaways
- US 9,089,418 is a structural composite device patent: it protects a specific shape-memory spring geometry (loop + twisted spring + two cross-over bends above twists forming two arms with tissue-contact ends) coupled to three delivery sleeves placed on both arms and one sleeve below the twists.
- Claim 1 is the enforceable core; dependent claims add substance-type limits (copper/spermicidal; hormone; dual copper+hormone) and a key quantitative limitation for copper sleeves (≤ about 200 mm² total surface area).
- Primary non-infringement strategies for competitors: remove or materially change (i) the shape-memory element, (ii) the twist-and-cross-over arm geometry, or (iii) the three-sleeve placement scheme tied to tissue-contact ends and “below the twists.”
- Copper-specific embodiments are additionally constrained by the surface-area cap in claim 4.
FAQs
1) What elements are most likely to be litigated for US 9,089,418 claim construction?
The phrases “elongate shape memory member,” “multiple twists,” “two bends … where … crosses over itself,” “two tissue contact surfaces,” and “third sleeve … below the twists,” plus “total surface area” for the ≤200 mm² limitation in claim 4.
2) Can a device with copper plus hormone avoid claim 5 while still infringing claim 1?
Yes if it does not include a “hormone delivery member coupled with the elongate member” as required by claim 5, while still meeting all claim 1 device-geometry and sleeve-structure requirements.
3) Does exceeding 200 mm² total sleeve surface area necessarily avoid infringement of the broader claims?
It avoids claim 4’s quantitative limitation, but it does not, by itself, avoid claim 1, claim 2, or claim 3, which do not include that cap.
4) What design change most directly targets non-infringement for claim 1?
Changing the device so it does not have the recited combination of (a) shape-memory member with twist-spring and cross-over two bends above twists creating two arms with tissue-contact ends and (b) the three sleeves with the specified positional relationships.
5) How do the dependent claims affect licensing leverage?
Dependent claims create clearer fallback positions tied to specific product configurations: copper-only (claim 3), copper with sleeve surface area cap (claim 4), and copper plus hormone (claim 5), plus hormone-only (claim 6).
References (APA)
- United States Patent 9,089,418.
